Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
NSPH > SEC Filings for NSPH > Form 8-K on 20-Jun-2013All Recent SEC Filings

Show all filings for NANOSPHERE INC



Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 20, 2013, the board of directors (the "Board") of Nanosphere, Inc. (the "Company") increased the size of the Board from five to seven directors and elected Gene Cartwright, Ph.D. and Erik Holmlin, Ph.D. to the Board.

Dr. Cartwright was the Chief Executive Officer of Omnyx, LLC, a joint venture between General Electric and the University of Pittsburgh Medical Center, from March 2008 to September 2012. From 2005 to 2008, Dr. Cartwright served as President of Molecular Diagnostics for GE Healthcare. From 2001 to 2005, Dr. Cartwright was the Divisional Vice President and General Manager of Molecular Diagnostics for Abbott Diagnostics. Dr. Cartwright received a Ph.D. in Chemistry from Stanford University, a Masters of Management from Northwestern University and a B.A. in Chemistry from Dartmouth College.

Dr. Holmlin is currently President and Chief Executive Officer of BioNano Genomics Inc., a commercial-stage company with a proprietary platform for genome mapping based on single molecule detection. From February 2010 to February 2011, Dr. Holmlin was an Entrepreneur in Residence at Domain Associates, LLC, a life sciences-dedicated venture capital firm, where one of his assignments was the role of President and Chief Executive Officer of GenVault Corporation, a provider of systems used for managing DNA collections. From July 2008 to November 2009 Dr. Holmlin was the Chief Commercial Officer of Exiqon A/S. In 2001, Dr. Holmlin led the formation of GeneOhm Sciences, Inc., a molecular diagnostics company that brought the first rapid tests for healthcare-associated infection (HAI) to market. In 2006, following GeneOhm's acquisition by Becton Dickinson, Dr. Holmlin served as Vice President of Marketing and Development for Becton Dickinson Diagnostics until July 2008. Dr. Holmlin holds a Ph.D. in Chemistry from California Institute of Technology, MBA degrees from the Haas School of Business at UC Berkeley and the Columbia University School of Business and an AB degree in Chemistry from Occidental College.

Except as set forth above, there are no agreements or understandings between the Company and Dr. Cartwright or Dr. Holmlin in respect of their service as directors of the Company, nor are there any other transactions in which Dr. Cartwright or Dr. Holmlin have any interests that are subject to disclosure as related person transactions pursuant to Item 404(a) of Regulation S-K.

The Company announced the election of Dr. Cartwright and Dr. Holmlin to the Board in a press release issued on June 20, 2013. A copy of the press release is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description

99.1 Press release of Nanosphere, Inc. dated June 20, 2013.

  Add NSPH to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NSPH - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.